Solid Tumors and Hematological Tumors
Conditions
Brief summary
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
Detailed description
It is urgent to select patients who will benefit from immunotherapy, so as to help the clinicians adjust the regimens and avoid unnecessary side effect. 18F-G1 is a new radioactive tracer targeting granzyme B, holding great promise in assessing early response to immunotherapy. This study will explore the safety of 18F-G1 PET/CT in patients with solid tumors and hematological tumors receiving immunotherapy, analyze its imaging features, and assess its efficacy in predicting early immunotherapy response and prognosis, so as to aid the clinicians in precise patient stratification and regimen adjustment.
Interventions
DRUG18F-G1
18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg
Sponsors
Peking University First Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team. 2. Subjects didn't receive previous immunotherapy. 3. There exists at least one measurable target lesion according to the RECIST 1.1. 4. ECOG performance status≤2. 5. The expected survival time is ≥6 months. 6. Effective contraceptive measures will be adopted during the study period and within 6 months after the study. 7. Willing and able to fully understand and sign the informed consent form.
Exclusion criteria
1. Women in the preconception period, pregnancy, or lactation period. 2. Combined with other malignant tumor. 3. Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy. 4. Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency. 5. Receiving radiotherapy or interventional therapy during the immunotherapy. 6. 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with 18F-G1-related adverse events (AEs). | 3 days after the injection of 18F-G1 | The absolute number of participants with AEs after the injection of 18F-G1 according to CTCAE 5.0. |
| The vivo accumulation and distribution of 18F-G1 in tumors and major healthy organs. | 40-60 minutes after the injection of 18F-G1 | The accumulation and distribution of 18F-G1 in tumors and major healthy organs, such as liver, lung, kidney, will be quantitatively and qualitatively examined. |
| the granzyme B specificity of 18F-G1 | 3 years | — |
| Assessing the early predictive value of 18F-G1 PET/CT for immunotherapy response. | 6 months | Participants' overall response will be assessed by RECIST 1.1 criteria or Lugano criteria at the time point of 6 months after immunotherapy. The tumor uptake of 18F-G1 will be compared between the responders and non-responders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the correlation of 18F-G1 accumulation in tumors to long term survival after immunotherapy. | 3 years | Participants will be categorized into groups with high or low 18F-G1 uptake in tumor lesions. The progression-free survival (PFS) as assessed by RECIST 1.1 criteria or Lugano criteria will be compared between the two groups. |
Contacts
Primary ContactCaixia Wu
Outcome results
None listed